Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Zeo ScientifiX ( (ZEOX) ).
On October 23, 2025, ZEO ScientifiX announced its readiness to leverage Florida’s new stem cell law, SB 1768, which took effect on July 1, 2025. The law allows licensed physicians to administer non-FDA-approved stem cell therapies for various medical indications, potentially expanding the market for ZEO’s regenerative products. The legislation is expected to increase demand for ZEO’s products, attract medical tourists, and facilitate revenue growth and clinical trial advancements. ZEO is also expanding its research and laboratory facilities to support its growth and maintain leadership in biologics research and compliance.
More about Zeo ScientifiX
ZEO ScientifiX™, Inc. is a clinical-stage biopharmaceutical company specializing in regenerative therapies, including birth tissue biologics, whole blood processing, and exosome nanoparticle science. The company operates from Nova Southeastern University’s Collaborative Center for Research and produces proprietary products such as Zofin™ and Patient Pure X™ (PPX™) in an FDA-registered, cGMP-compliant laboratory.
Average Trading Volume: 15,754
Technical Sentiment Signal: Buy
Current Market Cap: $12.45M
Find detailed analytics on ZEOX stock on TipRanks’ Stock Analysis page.